NorthWest Biotherapeutics Inc (NWBO)

[iclight]

The goal of any article by renowned oncologists is to move potential treatments forward and discuss trial failures, and at this point, NWBO is a failure yet LP is quite rich from selling BS (and CDMOs and shares).

NWBO certainly doesn't want a public debate or literally every oncologist not involved in the trial will easily shred any of Liau's poor arguments by simply pointing to FDA guidance, proper trial design, and standard trial reporting, including scheduling an IA in the protocol, performing the IA, and following DSMB guidance.

But first they will all laugh at the Swiss approval as precedents that LP is a sheister.